Garry Neil compensation by year
Avalo Therapeutics Summary Compensation Table · all 5 fiscal years held| Component | FY2020 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $372,932 | $468,900 | $475,000 | $532,500 | $590,000 |
| Bonus | $296,000 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $1,922,648 | $0 |
| Option awards | $2,019,872 | $730,928 | $434,112 | $4,255,801 | $2,732,298 |
| Non-equity incentive | $0 | $133,000 | $166,250 | $501,800 | $474,950 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $10,333 |
| Total | $2,688,804 | $1,332,828 | $1,075,362 | $7,212,749 | $3,807,581 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Avalo Therapeutics, Inc. DEF 14A filed April 10, 2026, accession 0001534120-26-000022, and prior-year filings.
How this page was built: the Avalo Therapeutics, Inc. filed document, accession 0001534120-26-000022. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 167,000 | $3,032,720 | — |
| RSU | 129,733 | $2,355,951 | — |
| Option | 411,000 | — | $8.04 |
| Option | 281,475 | — | $9.88 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Avalo Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Avalo Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Garry Neil · this page | Chief Executive Officer, President and principal executive officer | $3,807,581 |
| Taylor Boyd | Chief Business Officer | $3,219,751 |
| Mittie FACR | Chief Medical Officer | $1,780,557 |
| Mittie Doyle | Chief Medical Officer | $1,780,557 |
Board service
Avalo Therapeutics board · FY2023–FY2025How this board is paid
Company policy: Avalo Therapeutics pays directors a $40,000 cash retainer and $20,100 in Options. As stated in Avalo Therapeutics's FY2025 proxy.
The full Avalo Therapeutics compensation record
free company briefThis page is one person within Avalo Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Avalo Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Avalo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.